RemeGen Co., Ltd. Proposes Amendments to Enhance Corporate Governance

RemeGen Co. Ltd. Class H ( (HK:9995) ) has shared an announcement.

RemeGen Co., Ltd. has announced proposed amendments to its Articles of Association to enhance corporate governance and compliance. Key changes include the cancellation of the Supervisory Committee, with its functions being transferred to the Audit Committee, and adjustments to shareholder rights and meeting procedures. These amendments aim to align with regulatory standards and are subject to shareholder approval, reflecting the company’s commitment to maintaining robust governance structures.

The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.

More about RemeGen Co. Ltd. Class H

RemeGen Co., Ltd. is a biopharmaceutical company based in Yantai, China. It operates in the pharmaceutical industry, focusing on the development and commercialization of innovative drugs, particularly in the areas of oncology, autoimmune, and ophthalmic diseases.

Average Trading Volume: 9,367,111

Technical Sentiment Signal: Buy

Current Market Cap: HK$31.81B

Find detailed analytics on 9995 stock on TipRanks’ Stock Analysis page.